Diamond Equity Research Initiates Coverage on Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN)

New York, May 27, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research LLC, an equity research firm with a focus on small capitalization public companies has initiated coverage of Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN). The research summary below is from a report commissioned by Optimi Health Corp. and produced by Diamond Equity Research.The in-depth 40-page initiation report includes detailed information on Optimi Health’s business model, services, industry overview, financials, management profile, and risks.

The full research report is available below.

Optimi Health Initiation of Coverage

Highlights from the report include:

About Optimi Health Corp.

Optimi Health Corp. is a Canadian GMP-certified pharmaceutical manufacturer specializing in the regulated production and international export of MDMA and psilocybin for prescription-based mental health therapies.

About Diamond Equity Research

Diamond Equity Research is an equity research and corporate access firm focused on small capitalization companies. Diamond Equity Research is an approved sell-side provider on major institutional investor platforms.

For more information, visit https://www.diamondequityresearch.com.

Disclosures:

Diamond Equity Research LLC (“DER”) is being compensated by Optimi Health Corp. (the “Company”) for producing research materials regarding the Company and its securities, which is intended to subsidize the costs associated with the preparation of the report and the ongoing monitoring of the security; however, the views expressed in the report reflect those of Diamond Equity Research. Diamond Equity Research LLC (“DER”) is being compensated by Optimi Health Corp. (the “Company”) for producing research materials regarding the Company and its securities, which is intended to subsidize the costs associated with the preparation of the report and the ongoing monitoring of the security; however, the views expressed in the report reflect those of Diamond Equity Research. As of 05/27/26 the issuer has paid us US$25,000 for our annual company sponsored research services, which commenced 01/12/26 and is billed semiannually upfront, consisting of US$25,000 paid for the first six-month period and US$25,000 to be paid for the second six-month period starting 07/12/26, due upfront in each period for respective research services as part of a US$50,000 annual research term fee. Additional compensation may be received in future years if the engagement is renewed. Diamond Equity Research LLC may be compensated for non-research related services, including presenting at Diamond Equity Research investment conferences, press releases and other additional services. The non-research related service cost is dependent on the company, but usually do not exceed $5,000. The issuer has not paid us for non-research related services as of 05/27/2026. Issuers are not required to engage us for these additional services. Additional fees may have accrued since then. Although Diamond Equity Research company sponsored reports are based on publicly available information and although no investment recommendations are made within our company sponsored research reports, given the small capitalization nature of the companies we cover we have adopted an internal trading procedure around the public companies by whom we are engaged, with investors able to find such policy on our website public disclosures page. This report and press release do not consider individual circumstances and does not take into consideration individual investor preferences.This report is based on information we consider reliable, including the subject of the report.This report does not explicitly or implicitly affirm that the information contained in this document is accurate and/or comprehensive, and as such should not be relied on in such capacity. All information contained within this report is subject to change without any formal or other notice provided. Statements within this report may constitute forward-looking statements, these statements involve many risk factors and general uncertainties around the business, industry, and macroeconomic environment. Investors need to be aware of the high degree of risk in small capitalization equities including the complete potential loss of their investment. Investors can find various risk factors in the initiation report and in the respective financial filings for Optimi Health Corp.,which may not be comprehensive. Please review initiation report attached for full disclosures.

Attachment